Stephens Sara B, Morris Shaine A, Benjamin Renata H, Canfield Mark A, Shumate Charles J, Li Ruosha, Cazaban-Ganduglia Cecilia, Agopian A J
Department of Epidemiology, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA; Division of Pediatric Cardiology, Department of Pediatrics, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas, USA.
Division of Pediatric Cardiology, Department of Pediatrics, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas, USA.
JACC Adv. 2025 May 19;4(6 Pt 1):101812. doi: 10.1016/j.jacadv.2025.101812.
Despite previously improved survival among children with congenital heart defects (CHDs), U.S. population-level evaluations of survival within recent years are scarce.
The purpose of this study was to describe the survival landscape among children with CHDs in a large population-based birth defects registry overall and by CHD lesion.
This population-based cohort study evaluated 1999 to 2017 live births with ≥1 major CHD in the statewide Texas Birth Defects Registry. Variables included CHD lesion, demographics, gestational age at birth (term/preterm), low birthweight (<2,500 g at birth), among others. Kaplan-Meier analyses were used to describe survival to 7 days, 28 days, 1 year, 5 years, and 10 years of life. Kaplan-Meier survival estimates were generated for 1-year survival for CHDs overall by lesion, using log-rank tests assessing differences by exposure.
Of 61,656 children with CHDs, survival was 98.1% and 90.7% at 7 days and 10 years, respectively, and substantially varied by lesion (range, 50.0% to 97.3% 10-year survival). Survival longitudinally improved for complex lesions including hypoplastic left heart syndrome (48.7% 1-year survival for cases born 1999-2004 vs 64.8% in 2014-2017; P < 0.0001). One-year survival differed by maternal race/ethnicity (eg, 58.3% for cases with complex pulmonary atresia born to non-Hispanic Black mothers vs 80.5% for non-Hispanic White mothers, P = 0.01), sex, gestational age, birthweight, and extracardiac defect status.
One-year survival improved for most CHDs over recent decades, although survival varies widely by CHD and characteristics. Findings have implications for clinical counseling, population-level resource and research planning, and reinforce the need for mitigation of disparities among individuals with CHDs.
尽管先天性心脏病(CHD)患儿的生存率此前已有所提高,但近年来美国基于人群水平的生存评估却很少见。
本研究的目的是描述在一个大型基于人群的出生缺陷登记系统中,先天性心脏病患儿总体以及按先天性心脏病病变分类的生存情况。
这项基于人群的队列研究评估了德克萨斯州全州出生缺陷登记系统中1999年至2017年出生的患有≥1种主要先天性心脏病的活产儿。变量包括先天性心脏病病变、人口统计学特征、出生时的孕周(足月儿/早产儿)、低出生体重(出生时<2500克)等。采用Kaplan-Meier分析来描述至7天、28天、1年、5年和10岁时的生存率。通过病变对先天性心脏病总体的1年生存率进行Kaplan-Meier生存估计,并使用对数秩检验评估暴露差异。
在61656例先天性心脏病患儿中,7天和10年时的生存率分别为98.1%和90.7%,且因病变不同而有很大差异(10年生存率范围为50.0%至97.3%)。包括左心发育不全综合征在内的复杂病变的纵向生存率有所提高(1999 - 2004年出生病例的1年生存率为48.7%,而2014 - 2017年为64.8%;P < 0.0001)。1年生存率因母亲的种族/族裔(例如,非西班牙裔黑人母亲所生的复杂肺动脉闭锁病例的1年生存率为58.3%,而非西班牙裔白人母亲为80.5%,P = 0.01)、性别、孕周、出生体重和心脏外缺陷状况而有所不同。
近几十年来,大多数先天性心脏病的1年生存率有所提高,尽管生存率因先天性心脏病类型和特征而有很大差异。这些发现对临床咨询、人群水平的资源和研究规划具有重要意义,并强化了缓解先天性心脏病患者之间差异的必要性。